Explaining cancer to your patient – Cancer is a disease of our genes
Cancer is caused when abnormalities in DNA (for example, mutations) lead to changes in a gene’s function, to promote uncontrollable cell growth, tumor survival, and metastasis.1 While some genetic mutations are inherited, which may lead to an increased risk of cancer formation, other mutations, called genomic mutations, are formed and present only within cancer (tumor) cells.1
Your patient can learn more about genes and cancer with the American Cancer Society.
Reference: 1. American Cancer Society. Genes and cancer. Available at: https://www.cancer.org/cancer/understanding-cancer/genes-and-cancer.html. Accessed September 2024.
Precision medicine in cancer means working towards a targeted treatment plan based on comprehensive biomarker profiling
The comprehensive biomarker profile of a tumor can be used to make a diagnosis, to determine treatment options based on gene mutations, and to evaluate the effectiveness of treatment.1,2 Some therapies targeting specific genomic changes are approved and available for use in clinical practice, while many are currently under investigation in clinical studies.1,2 Biomarker testing can provide a molecular profile of your patient's tumor, which may give information on whether an approved therapy or clinical study could be an option.1,2
Your patient can learn more about precision medicine with the American Cancer Society.
References: 1. American Cancer Society. Biomarker tests and cancer treatment. Available at: https://www.cancer.org/cancer/diagnosis-staging/tests/biomarker-tests.html. Accessed September 2024; 2. American Cancer Society. Precision or personalized medicine. Available at: https://www.cancer.org/cancer/managing-cancer/treatment-types/precision-medicine.html. Accessed September 2024.
Discussing next-generation sequencing (NGS) with your patient – NGS testing can identify gene mutations
NGS is a method of biomarker testing which identifies any genomic mutations.1 Tissue from a patient’s tumor that has been removed either by biopsy or surgery can be assessed by NGS.1 For some patients, a blood sample may be used for NGS testing.1 NGS can provide important information to determine available treatments or clinical study options for your patient.1 The TP53 Y220C mutation results in a mutated p53 Y220C protein which is a key treatment target in cancer that has been identified in >30 different solid tumor types.2–6 NGS can identify the TP53 Y220C mutation.7
Your patient can learn more about NGS testing with JAMA Oncology.
References: 1. Ewalt MD, et al. JAMA Oncol. 2019;5:1076; 2. Blanden AR, et al. Drug Discov Today. 2015;20:1391–1397; 3. Baud MGJ, et al. Eur J Med Chem. 2018;152:101–114; 4. Tang Y, et al. J Phys Chem B. 2021;125:10138–10148; 5. FoundationInsights™. A proprietary database used under license with review and approval from Foundation Medicine®. Available at: https://www.foundationmedicine.com/service/genomic-data-solutions. Accessed May 2024; 6. Schram A, et al. Poster presentation at AACR-NCI-EORTC 2023, Boston, USA. October 11–15, 2023; 7. Dumbrava EE, et al. Oral presentation at ASCO 2022, Chicago, USA. June 3–7, 2022.
Further information on clinical studies
Your patient can learn more about clinical studies with the National Cancer Institute, American Cancer Society, and European Medicines Agency.
If your patient is interested in taking part in a clinical trial listed on clinicaltrials.gov, the Leal Health service can help them find the right trial, for free. Share this link with your patient to provide them with more information.
To learn more about rezatapopt (also known as PC14586) in the PYNNACLE study, please visit clinicaltrials.gov.
Please contact the PMV Pharmaceuticals Clinical Study Information Center
+1 (609) 235-4038
clinicaltrials@pmvpharma.com
Rezatapopt is an investigational agent that has not been approved by the US FDA, EMA, or any other regulatory agency for the treatment of cancer.
Images do not depict actual trial participants.
MA-586-0035 October 2024